Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.

Lightfoot AJ, Breyer BN, Rosevear HM, Erickson BA, Konety BR, O'Donnell MA.

Urol Oncol. 2014 Jan;32(1):35.e15-9. doi: 10.1016/j.urolonc.2013.01.009. Epub 2013 Mar 17.

2.

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.

Cockerill PA, Knoedler JJ, Frank I, Tarrell R, Karnes RJ.

BJU Int. 2016 Mar;117(3):456-62. doi: 10.1111/bju.13088. Epub 2015 May 23.

3.

Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer.

Breyer BN, Whitson JM, Carroll PR, Konety BR.

Urol Oncol. 2010 Sep-Oct;28(5):510-4. doi: 10.1016/j.urolonc.2008.11.019. Epub 2009 Jan 26.

4.

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. Review.

5.

Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.

Järvinen R, Marttila T, Kaasinen E, Rintala E, Aaltomaa S, Kallio J, Liukkonen T, Puolakka VM, Seppänen M, Tuhkanen K, Vaarala M, Viitanen J, Boström PJ; FinnBladder Group..

Eur Urol. 2015 Oct;68(4):611-7. doi: 10.1016/j.eururo.2015.02.022. Epub 2015 Mar 5.

PMID:
25748117
6.

Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.

Sternberg IA, Dalbagni G, Chen LY, Donat SM, Bochner BH, Herr HW.

J Urol. 2013 Nov;190(5):1686-91. doi: 10.1016/j.juro.2013.04.120. Epub 2013 May 7.

PMID:
23665400
7.

SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.

Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz HJ, Lee CT, Wilson SS, Benson M, Lerner SP, Tangen CM, Thompson IM.

J Urol. 2013 Oct;190(4):1200-4. doi: 10.1016/j.juro.2013.04.031. Epub 2013 Apr 15.

8.

Intravesical gemcitabine for non-muscle invasive bladder cancer.

Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD009294. doi: 10.1002/14651858.CD009294.pub2. Review.

PMID:
22259002
9.

The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.

Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat SF, Chun F.

J Urol. 2013 Sep;190(3):857-62. doi: 10.1016/j.juro.2013.03.097. Epub 2013 Mar 29.

PMID:
23545101
10.

Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.

Solsona E, Madero R, Chantada V, Fernandez JM, Zabala JA, Portillo JA, Alonso JM, Astobieta A, Unda M, Martinez-Piñeiro L, Rabadan M, Ojea A, Rodriguez-Molina J, Beardo P, Muntañola P, Gomez M, Montesinos M, Martinez Piñeiro JA; Members of Club Urológico Español de Tratamiento Oncológico..

Eur Urol. 2015 Mar;67(3):508-16. doi: 10.1016/j.eururo.2014.09.026. Epub 2014 Oct 6.

PMID:
25301758
12.

Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer.

Weiss BE, Pietzak EJ, Wein AJ, Malkowicz SB, Guzzo TJ.

Can J Urol. 2015 Aug;22(4):7876-81.

PMID:
26267025
13.
14.

Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.

Halachmi S, Moskovitz B, Maffezzini M, Conti G, Verweij F, Kedar D, Sandri SD, Nativ O, Colombo R.

Urol Oncol. 2011 May-Jun;29(3):259-64. doi: 10.1016/j.urolonc.2009.02.012. Epub 2009 Apr 22.

PMID:
19395285
16.

A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.

Chen CH, Yang HJ, Shun CT, Huang CY, Huang KH, Yu HJ, Pu YS.

Urol Oncol. 2012 Jul-Aug;30(4):421-7. doi: 10.1016/j.urolonc.2010.06.012. Epub 2010 Sep 25.

PMID:
20870427
17.

Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.

Colombo R, Rocchini L, Suardi N, Benigni F, Colciago G, Bettiga A, Pellucchi F, Maccagnano C, Briganti A, Salonia A, Rigatti P, Montorsi F.

Eur Urol. 2012 Nov;62(5):797-802. doi: 10.1016/j.eururo.2012.05.032. Epub 2012 May 18.

PMID:
22633362
18.
19.

Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.

Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, Donat MS, Herr HW, Bajorin D.

J Clin Oncol. 2006 Jun 20;24(18):2729-34.

PMID:
16782913
20.

Supplemental Content

Support Center